MCRB

Seres Therapeutics Inc

MCRB.US serestherapeutics.com + Research + Basket
CIK 0001609809
Employees 66
Phone 617 945 9626
Fiscal year end December
IPO Jun 26, 2015
Address 101 Cambridgepark Drive, Cambridge, MA, United States, 02140
1.81
-0.17 (-8.59%)
USD · NASDAQ
52-week range
1.98
29.98
Trading at 0% of the 52-week range
Market Cap
19.89M
P/E Ratio
0.00
Forward P/E
10.26
Book Value
3.51
Div. Yield
N/A
% Institutions
22.99%
% Insiders
11.49%

1 Year

-88.5%

3 Year

-92.8%

10 Year

-99.1%
Description

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Actions

Add an action for MCRB.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Richard N. Kender B.S., M.B.A. Interim CEO & Executive Chair 1956
Dr. Matthew R. Henn Ph.D. President & Chief Scientific Officer 1975
Ms. Marella Thorell CPA Executive VP, CFO & Treasurer 1967
Mr. Thomas J. DesRosier Esq., J.D. Executive VP, Chief Legal Officer & Secretary 1955
Ms. Kelly Brady M.S. Executive VP & COO 1984
Mr. Chris McChalicher Executive VP & CTO NA
Dr. Dennis M. Walling M.D. Senior VP of Clinical Development & Head of Clinical Research NA
Ms. Ann Kurowski Senior Vice President of Regulatory Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Nov 15, 2025 Eric D Shaff N/A Sale 217.00 $17.30 $3.75K SEC
Nov 15, 2025 Matthew R Henn N/A Sale 1.26K $17.30 $21.75K SEC
Nov 15, 2025 Thomas Desrosier N/A Sale 76.00 $17.30 $1.31K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Flagship Ventures Management, Inc. 1.16M Jun 30, 2026 11.51% $0.59 0.00%
Vanguard Capital Management, LLC 287.78K Jun 30, 2026 2.86% $0.00 -2.16%
Marshall Wace Asset Management Ltd 172.25K Jun 30, 2026 1.71% $0.00 23.44%
Vontobel Holding Ltd. 122.98K Jun 30, 2026 1.22% $0.00 -11.19%
BlackRock Inc 111.00K Jun 30, 2026 1.11% $0.00 8.80%
Geode Capital Management, LLC 79.97K Jun 30, 2026 0.80% $0.00 6.87%
Susquehanna International Group, LLP 58.33K Jun 30, 2026 0.58% $0.00 -44.63%
Vanguard Fiduciary Trust Co 48.69K Jun 30, 2026 0.48% $0.00 22.81%
State Street Corp 33.90K Jun 30, 2026 0.34% $0.00 0.00%
Lion Point Capital, LP 31.57K Jun 30, 2026 0.31% $1.19 0.00%
Charles Schwab Investment Management Inc 31.05K Jun 30, 2026 0.31% $0.00 -1.84%
American Century Companies Inc 28.31K Jun 30, 2026 0.28% $0.00 -54.57%
XTX Topco Ltd 20.73K Jun 30, 2026 0.21% $0.00 0.00%
The Goldman Sachs Group Inc 15.23K Jun 30, 2026 0.15% $0.00 0.00%
Northern Trust Corp 14.77K Jun 30, 2026 0.15% $0.00 0.00%
Amvescap Plc. 12.97K Jun 30, 2026 0.13% $0.00 -10.81%
Morgan Stanley - Brokerage Accounts 12.14K Jun 30, 2026 0.12% $0.00 -44.06%
Citadel Advisors Llc 10.50K Jun 30, 2026 0.10% $0.00 0.00%
SIMPLEX TRADING, LLC 4.60K Jun 30, 2026 0.05% $0.00 49.77%
SBI Securities Co Ltd 4.18K Jun 30, 2026 0.04% $0.00 20.10%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 206.17K 2.05% ▲ 0.00% Sep 30, 2026
2 Fidelity Extended Market Index 39.51K 0.39% ▲ 7.85% Aug 31, 2026
3 Abante Quant Value FI 24.64K 0.25% ▲ 87.61% Aug 31, 2026
4 iShares Micro-Cap ETF 24.22K 0.24% ▼ 0.68% Sep 30, 2026
5 Fidelity Total Market Index 13.87K 0.14% ▲ 0.00% Aug 31, 2026
6 Invesco RAFI US 1500 Small-Mid ETF 12.92K 0.13% ▲ 0.00% Sep 30, 2026
7 Fidelity Series Total Market Index 10.14K 0.10% ▲ 0.00% Aug 31, 2026
8 Goldman Sachs Absolute Ret Trckr Instl 10.07K 0.10% ▲ 297.51% Jun 30, 2026
9 EA Bridgeway Ultra-Small Company Mkt ETF 7.40K 0.07% ▲ 0.00% Sep 30, 2026
10 Vanguard Balanced Index Inv 4.39K 0.04% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $19.89M
EBITDA: $-74.78M
PEG Ratio: $-0.11
Book Value: $3.51
Earnings/Share: $-2.42
Profit Margin: 0.00%
Operating Margin: -2,101.36%
ROA (TTM): -39.85%
ROE (TTM): -66.57%
Revenue (TTM): $1.88M
Revenue/Share (TTM): $0.20
Earnings Growth (YOY): -91.90%
Revenue Growth (YOY): -93.40%

Valuation Metrics

Enterprise Value: $60.94M
Trailing P/E: 0.00
Forward P/E: 10.26

Shares Statistics

Shares Outstanding: 10.04M
Shares Float: 8.74M
% Insiders: 11.49%
% Institutions: 22.99%
Short % Float: 4.05%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$789.00K
Cost of Goods Sold
adjust
$-4.13M
Gross Profit
subtotal
$-3.34M
SG&A
adjust
$-39.16M
R&D
adjust
$-49.06M
Other Operating Expense
adjust
$-2.41M
Operating Income
subtotal
$-93.97M
Other / Non-Operating Items
adjust
$99.67M
Net Income
subtotal
$5.70M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MCRB.US!